Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma

Abstract Background and Aim The purpose of this study was to analyze factors associated with the overall survival (OS) of atezolizumab/bevacizumab combination therapy for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients with ineffective therapy and those who discontinued...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshihiko Yano, Atsushi Yamamoto, Takuya Mimura, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Hirotaka Hirano, Soo Ki Kim, Yuri Hatazawa, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Takanori Matsuura, Ryutaro Yoshida, Naoki Asaji, Eiichiro Yasutomi, Yuuki Shiomi, Akihiro Minami, Shohei Komatsu, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama
Formato: Artículo
Lenguaje:English
Publicado: Wiley 2023-07-01
Colección:JGH Open
Materias:
adverse event
hepatocellular carcinoma
immune checkpoint inhibitor
Acceso en línea:https://doi.org/10.1002/jgh3.12932

Internet

https://doi.org/10.1002/jgh3.12932

Ejemplares similares